SCYNEXIS to Host a Conference Call to Discuss Lead Anti-Infective Candidate SCY-078 Data Presented at 27th ECCMID
April 21 2017 - 9:00AM
SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering
innovative anti-infective therapies for difficult-to-treat and
often life-threatening infections, today announced that it will
hold a conference call at 4:05 p.m. ET on Tuesday, April 25, 2017
to discuss in vitro and clinical data related to its lead
candidate, SCY-078, presented at the 27th European Congress of
Clinical Microbiology and Infectious Diseases (ECCMID), April 22 to
25, 2017, in Vienna, Austria. SCY-078 will be featured in two
oral and six poster presentations at the Congress.
SCYNEXIS management will be joined by global thought
leaders:
- Mahmoud Ghannoum, Ph.D., Professor and Director of the Center
for Medical Mycology at Case Western Reserve University and
University Hospitals Cleveland Medical Center
- Oliver Cornely, M.D., Professor of Internal Medicine and
Medical Director, Clinical Trials Center Cologne at the University
of Cologne in Germany
Conference Call Details: U.S. Dial-In Number:
844-309-3707 International Dial-In Number: 661-378-9467 Conference
ID: 12180429
The slide and audio webcast can be accessed by visiting the
Investors section of the Company’s website
at http://ir.scynexis.com. A replay of the webcast will be
available shortly after the conclusion of the call and will be
archived on the Company’s website for 30 days.
About SCY-078SCY-078 is an oral and IV
antifungal agent in Phase 2 clinical development for the treatment
of fungal infections caused
by Candida and Aspergillus species. SCY-078 is
a triterpenoid, semi-synthetic derivative of the natural product
enfumafungin—a structurally distinct and novel class of glucan
synthase inhibitor. SCY-078 combines the well-established activity
of glucan synthase inhibitors (similar to echinocandins) with the
flexibility of having IV and oral formulations (similar to azoles).
By belonging to a chemical class distinct from other antifungals,
SCY-078 has shown in vitro and in vivo activity
against multi-drug resistant pathogens, including azole- and
echinocandin-resistant strains. The U.S. Food and Drug
Administration granted Fast Track, Qualified Infectious Disease
Product and Orphan Drug Designations for the oral and IV
formulations of SCY-078 for the indications of invasive candidiasis
(including candidemia) and invasive aspergillosis.
About SCYNEXIS, Inc.SCYNEXIS, Inc. is a
biotechnology company committed to positively impacting the
lives of patients suffering from difficult-to-treat and often
life-threatening infections by delivering innovative anti-infective
therapies. The SCYNEXIS team has extensive experience in the life
sciences industry, discovering and developing more than 30
innovative medicines over a broad range of therapeutic areas. The
Company’s lead product candidate, SCY-078, is the first
representative of a novel intravenous and oral triterpenoid
antifungal family and is in Phase 2 clinical development for the
treatment of several fungal infections, including serious and
life-threatening invasive fungal infections. For more
information, visit www.scynexis.com.
Forward-Looking StatementStatements contained
in this press release maybe, "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited, to: risks
inherent in SCYNEXIS' ability to successfully develop SCY-078,
including SCYNEXIS' ability to resolve the FDA's concerns to lift
the clinical hold and obtain FDA approval for SCY-078; the expected
costs of studies and when they might begin or be concluded; and
SCYNEXIS' reliance on third parties to conduct SCYNEXIS' clinical
studies. These and other risks are described more fully in
SCYNEXIS' filings with the Securities and Exchange Commission,
including without limitation, its most recent Annual Report on Form
10-K under the caption "Risk Factors" and other documents
subsequently filed with or furnished to the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. SCYNEXIS
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
CONTACT:
Media Relations
Cammy Duong
MacDougall Biomedical Communications
Tel: 781-235-3060
cduong@macbiocom.com
Investor Relations
Susan Kim
Argot Partners
Tel: 212-203-4433
susan@argotpartners.com
Scynexis (NASDAQ:SCYX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Scynexis (NASDAQ:SCYX)
Historical Stock Chart
From Apr 2023 to Apr 2024